{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T17:50:04Z","timestamp":1776534604623,"version":"3.51.2"},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1124\/dmd.124.001806","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T18:30:16Z","timestamp":1720722616000},"page":"1029-1036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Usefulness of Determining Plasma and Tissue Concentrations of Phosphorodiamidate Morpholino Oligonucleotides to Estimate Their Efficacy in Duchenne Muscular Dystrophy Patients"],"prefix":"10.1016","volume":"52","author":[{"given":"Shunji","family":"Imai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Tone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rei","family":"Mitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumpei","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsubasa","family":"Kameyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutomi","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.124.001806_bib1","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1080\/17512433.2022.2136166","article-title":"Clinical pharmacology of siRNA therapeutics: current status and future prospects","volume":"15","author":"Abosalha","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1124\/dmd.124.001806_bib2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nm1345","article-title":"Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology","volume":"12","author":"Alter","year":"2006","journal-title":"Nat Med"},{"key":"10.1124\/dmd.124.001806_bib3","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1093\/hmg\/ddt341","article-title":"Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-\u03b12 chain-null congenital muscular dystrophy mice","volume":"22","author":"Aoki","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1124\/dmd.124.001806_bib4","doi-asserted-by":"crossref","first-page":"10549","DOI":"10.1021\/acs.analchem.2c02111","article-title":"Intracellular Absolute Quantification of Oligonucleotide Therapeutics by NanoSIMS","volume":"94","author":"Becquart","year":"2022","journal-title":"Anal Chem"},{"key":"10.1124\/dmd.124.001806_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/nat.2019.0840","article-title":"RT-qPCR Methods to Support Pharmacokinetics and Drug Mechanism of Action to Advance Development of RNAi Therapeutics","volume":"30","author":"Castellanos-Rizaldos","year":"2020","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/dmd.124.001806_bib7","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.omtn.2022.08.033","article-title":"Exon skipping induces uniform dystrophin rescue with dose-dependent restoration of serum miRNA biomarkers and muscle biophysical properties","volume":"29","author":"Chwalenia","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/dmd.124.001806_bib8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.omtn.2023.07.018","article-title":"25 years of maturation: A systematic review of RNAi in the clinic","volume":"33","author":"Corydon","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/dmd.124.001806_bib9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular uptake and trafficking of antisense oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1124\/dmd.124.001806_bib10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1124\/dmd.124.001806_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.omtn.2022.08.019","article-title":"A cell-penetrating peptide enhances delivery and efficacy of phosphorodiamidate morpholino oligomers in mdx mice","volume":"30","author":"Gan","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/dmd.124.001806_bib12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/17425255.2023.2283524","article-title":"Predicting the pharmacokinetics and pharmacodynamics of antisense oligonucleotides: an overview of various approaches and opportunities for PBPK\/PD modelling","volume":"19","author":"Gao","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.124.001806_bib13","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1038\/s41598-017-06534-z","article-title":"Quantitative diagnostic imaging of cancer tissues by using phosphor-integrated dots with ultra-high brightness","volume":"7","author":"Gonda","year":"2017","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.124.001806_bib14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.omtn.2023.05.022","article-title":"Nucleic acid amphiphiles: Synthesis, properties, and applications","volume":"33","author":"Gubu","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/dmd.124.001806_bib15","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.3390\/cells12192395","article-title":"Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide","volume":"12","author":"Haque","year":"2023","journal-title":"Cells"},{"key":"10.1124\/dmd.124.001806_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/jgm.1288","article-title":"In vivo comparison of 2\u2019-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping","volume":"11","author":"Heemskerk","year":"2009","journal-title":"J Gene Med"},{"key":"10.1124\/dmd.124.001806_bib17","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/mt.2010.72","article-title":"Preclinical PK and PD studies on 2\u2019-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model","volume":"18","author":"Heemskerk","year":"2010","journal-title":"Mol Ther"},{"key":"10.1124\/dmd.124.001806_bib18","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1056\/NEJMe0707795","article-title":"Skipping toward personalized molecular medicine","volume":"357","author":"Hoffman","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.124.001806_bib19","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1124\/dmd.123.001425","article-title":"Prediction of human pharmacokinetics of phosphorodiamidate morpholino oligonucleotides in Duchenne muscular dystrophy patients using viltolarsen","volume":"51","author":"Imai","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001806_bib20","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3390\/cimb43030090","article-title":"Renadirsen, a Novel 2\u2019OMeRNA\/ENA\u00ae Chimera Antisense Oligonucleotide, Induces Robust Exon 45 Skipping for Dystrophin In Vivo","volume":"43","author":"Ito","year":"2021","journal-title":"Curr Issues Mol Biol"},{"key":"10.1124\/dmd.124.001806_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0713","article-title":"Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy","volume":"10","author":"Komaki","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1124\/dmd.124.001806_bib22","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/acn3.51235","article-title":"Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1\/2 study","volume":"7","author":"Komaki","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1124\/dmd.124.001806_bib23","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.3390\/cells12182253","article-title":"Therapeutic Oligonucleotides: An Outlook on Chemical Strategies to Improve Endosomal Trafficking","volume":"12","author":"Mangla","year":"2023","journal-title":"Cells"},{"key":"10.1124\/dmd.124.001806_bib24","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1124\/dmd.121.000428","article-title":"The Nonclinical Disposition and Pharmacokinetic\/Pharmacodynamic Properties of N-Acetylgalactosamine-Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human","volume":"50","author":"McDougall","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001806_bib25","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1124\/dmd.121.000417","article-title":"Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs","volume":"50","author":"Migliorati","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001806_bib26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.omtn.2019.01.008","article-title":"Scavenger Receptor Class A1 Mediates Uptake of Morpholino Antisense Oligonucleotide into Dystrophic Skeletal Muscle","volume":"14","author":"Miyatake","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/dmd.124.001806_bib27","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.3390\/molecules27123662","article-title":"Dystrophin Protein Quantification as a Duchenne Muscular Dystrophy Diagnostic Biomarker in Dried Blood Spots Using Multiple Reaction Monitoring Tandem Mass Spectrometry: A Preliminary Study","volume":"27","author":"Nimer","year":"2022","journal-title":"Molecules"},{"key":"10.1124\/dmd.124.001806_bib28","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41467-017-00924-7","article-title":"Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle","volume":"8","author":"Novak","year":"2017","journal-title":"Nat Commun"},{"key":"10.1124\/dmd.124.001806_bib29","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1124\/dmd.119.087395","article-title":"Metabolism and disposition of volanesorsen, a 29-O-(2 methoxyethyl) antisense oligonucleotide, across species","volume":"47","author":"Post","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001806_bib30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1091581811403505","article-title":"Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of duchenne muscular dystrophy","volume":"30","author":"Sazani","year":"2011","journal-title":"Int J Toxicol"},{"key":"10.1124\/dmd.124.001806_bib31","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/17425255.2021.1992382","article-title":"Antisense oligonucleotides: absorption, distribution, metabolism, and excretion","volume":"17","author":"Shadid","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.124.001806_bib32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/dmd.124.001806_bib33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/nat.2022.0054","article-title":"Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs","volume":"33","author":"Takakusa","year":"2023","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/dmd.124.001806_bib33A","series-title":"Progress in Drug Metabolism","first-page":"249","article-title":"Whole-body autoradiography","author":"Ullberg","year":"1981"},{"key":"10.1124\/dmd.124.001806_bib34","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.omtn.2018.09.017","article-title":"NS-065\/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy","volume":"13","author":"Watanabe","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/dmd.124.001806_bib35","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/dmd.106.012401","article-title":"Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100","volume":"35","author":"Yu","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001806_bib36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41536-018-0045-4","article-title":"Humanizing the mdx mouse model of DMD: the long and the short of it","volume":"3","author":"Yucel","year":"2018","journal-title":"NPJ Regen Med"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624158989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624158989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.124.001806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:56:05Z","timestamp":1740056165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624158989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0090955624158989"],"URL":"https:\/\/doi.org\/10.1124\/dmd.124.001806","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Usefulness of Determining Plasma and Tissue Concentrations of Phosphorodiamidate Morpholino Oligonucleotides to Estimate Their Efficacy in Duchenne Muscular Dystrophy Patients","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.124.001806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}